A pre-fermented symbiotic matrix based on a cereal suspension containing encapsulated probiotics and prebiotics, the manufacturing process and the corresponding use are disclosed. The invention complements the actual functional food market solving problems inherent to reduced shelf-life of foods due to loss of probiotic viability to values below the minimum limits needed to promote biological activity. The invention also improves the enzymatic process in the preparation of the cereal base and the fermentative process conditions at different levels, namely the ability to control the concentration of sugars in the cereal suspension without adding sugars, increase protein and fiber content, reduce fermentation time to reduce energy consumption during the process and reduce the risk of contamination as well as promote long term microbial stability maintenance. The invention is designed for cases where intolerance and/or allergy to dairy products occur, as wells for the pharmaceutical, cosmetic and food industries, including pet food.

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

A method for improving body shape and improving skin condition using a noni fruit ferment is provided, and the method includes: administrating a composition to a subject in need thereof. The composition includes an effective amount of noni fruit ferment. The noni fruit ferment is prepared by (a) mixing glucose and noni fruit with water for extraction, to obtain a noni fruit broth, and (b) fermenting the noni fruit broth with a plurality of bacteria strains. The bacteria strains include yeast, lactic acid bacteria, and acetic acid bacteria. In step (b), the noni fruit broth and the bacteria strains are irradiated with a red light source with a wavelength of 620 nm to 750 nm. In addition, the noni fruit ferment also has at least one of the following functions: removing free radicals, improving defecation status, and improving gastrointestinal motility.

A method for improving body shape and improving skin condition using a noni fruit ferment is provided, and the method includes: administrating a composition to a subject in need thereof. The composition includes an effective amount of noni fruit ferment. The noni fruit ferment is prepared by (a) mixing glucose and noni fruit with water for extraction, to obtain a noni fruit broth, and (b) fermenting the noni fruit broth with a plurality of bacteria strains. The bacteria strains include yeast, lactic acid bacteria, and acetic acid bacteria. In step (b), the noni fruit broth and the bacteria strains are irradiated with a red light source with a wavelength of 620 nm to 750 nm. In addition, the noni fruit ferment also has at least one of the following functions: removing free radicals, improving defecation status, and improving gastrointestinal motility.

L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.

The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

Provided herein are methods of treating (e.g., inhibiting, modulating, reversing, or reducing the severity of at least one symptom of) a dysbiosis in a subject, the method comprising administering an effective amount of a composition described herein (e.g., a composition comprising polyglucosamine-arginine (PAAG)).

Provided herein are methods of treating (e.g., inhibiting, modulating, reversing, or reducing the severity of at least one symptom of) a dysbiosis in a subject, the method comprising administering an effective amount of a composition described herein (e.g., a composition comprising polyglucosamine-arginine (PAAG)).